Background: The indication for carotid endarterectomy (CEA) is uncertain in patients with asymptomatic severe ($60% luminal narrowing according to the North American Symptomatic Carotid Endarterectomy Trial criteria) carotid stenosis (ASCS), especially in the very elderly, because current evidence suggests that the risk of future stroke has been dropping in the past two decades owing to the recent advances in medical therapy. The aim of this observational study was to compare early and late outcomes in patients $80 years old with ASCS treated with CEA plus best medical treatment (BMT) or with BMT alone. Methods: From 2005 to 2012, 69 octogenarians with ASCS underwent CEA plus BMT (group 1), and another 54 received BMT alone (group 2). All operations were eversion CEAs. BMT included lipid-lowering drugs, new antiplatelet and antihypertensive agents, avoidance of smoking, careful blood pressure and glycemic control, and lifestyle changes. Followup with serial ultrasonographic examination was obtained in 118 patients for a median 4.4-year period.
Asymptomatic carotid artery stenosis with $50% luminal narrowing is a common finding in aging individuals, with 7% to 9% of the population affected by the age of 75 years. 1 Large randomized clinical trials (RCTs), such as the Asymptomatic Carotid Atherosclerotic Study (ACAS) 2 and the Asymptomatic Carotid Surgery Trial (ACST), 3 have demonstrated the therapeutic benefits of carotid endarterectomy (CEA) over best medical treatment (BMT) for patients with asymptomatic severe carotid stenosis (ASCS), albeit with a significantly lower absolute benefit than in patients with symptomatic carotid stenosis, 4 ,5 mainly because of the low risk of stroke in medically treated patients. Since the first RCTs were conducted, significant improvements have been made in the medical management of carotid disease, which involves lipidlowering drugs such as statins, latest-generation antiplatelet and antihypertensive drugs, better glycemic control, and lifestyle changes, so there is now convincing evidence of a drop in the risk of ischemic cerebrovascular events as a result. 6 This has prompted some authors to conclude that the previously reported significant benefit of CEA over BMT was due to a suboptimal medical therapy, 7 to question the appropriateness of CEA for patients with ASCS, and to suggest that BMT should replace CEA as the standard of care for such patients. [7] [8] [9] On the other hand, recent prospective data from the Reduction of Atherothrombosis for Continued Health (REACH) registry showed a relatively high incidence of cerebrovascular ischemic events occurring within 12 months in a large cohort of patients with ASCS, even though most of them were taking statins and antihypertensive drugs at baseline. 10 In this scenario, the optimal management for primary prevention of stroke in patients with ASCS remains controversial. Despite evidence of the incidence of stroke and stroke-related mortality increasing dramatically with advancing age, and given that elderly people are typically seen in daily clinical practice, concern has been voiced about the role of CEA for patients with ASCS aged 80 years or more because of the inherent risks of surgery and uncertainty surrounding the long-term survival of this age group after CEA. 11, 12 The purpose of this observational study was to analyze the perioperative (30-day) and long-term outcomes of CEA plus BMT in patients older than 80 years with ASCS. A cohort of patients with ASCS in the same age group who were treated with BMT alone during the same period served as a control group.
METHODS
Our Institutional Review Board and Ethics Committee approved the study. All patients gave their written informed consent to the analysis of their records and the publication of the findings.
Details of all consecutive patients undergoing primary CEA at our tertiary referral center between 2005 and 2012 for symptomatic and asymptomatic carotid lesionsd according to the North American Symptomatic Carotid Endarterectomy Trial (NASCET) 4 and the ACAS 2 recommendations, respectivelydwere prospectively stored in a vascular registry. During this period, 384 patients underwent 444 primary CEAs (60 were bilateral) for symptomatic carotid disease, and another 198 patients with ASCS underwent 228 primary CEAs (30 were bilateral). The registry was queried to identify patients with ASCS ($60% luminal narrowing according to the NASCET criteria) aged 80 years or more who were treated with CEA plus BMT; this yielded 69 patients who underwent 72 CEAs (group 1). For the purpose of this study, we also considered data from the electronic medical records concerning another 54 patients aged 80 years or more with ASCS (group 2) who were referred to our institution during the study period for surgical revascularization but did not undergo CEA, regardless of comorbidities, because their carotid lesion was stable (homogeneous isoechoic plaque with no evidence of ulceration or intraplaque hemorrhage) on B-mode ultrasound (43 of 54; 79.6%) or because they refused surgery after being informed of the pros and cons (16 of 54; 29.6%). None of the patients in group 2 were refused CEA for a limited life expectancy (<3-5 years). As in group 1, all group 2 patients were given BMT, including combination of antiplatelet drugs (aspirin 100 mg/d or clopidogrel 75 mg/d if aspirin was contraindicated), antihypertensive and antidiabetic agents, and lipid-lowering drugs (atorvastatin 40 or 80 mg/d, aiming for a low-density lipoprotein level <100 mg/dL); they were advised not to smoke and to adopt lifestyle changes as necessary and scheduled for strict clinical and ultrasonographic follow-up.
Patients scheduled for CEA with concomitant coronary artery bypass grafting or concurrent surgery for associated supra-aortic trunk lesions were excluded from the present analysis. All patients' demographic and clinical data were recorded on a standardized form, including potential atherosclerotic risk factors, anatomic and clinical variables, preoperative medication, details of surgery, and all perioperative outcomes. For most patients, the diagnosis of carotid disease was based on preoperative duplex ultrasound scans, combined with magnetic resonance angiography, computed tomography (CT) angiography, or digital subtraction angiography in selected patients (ie, those who had either a pseudo-occlusion on duplex ultrasound or a stenosis of the carotid intracranial segment detected by transcranial color-coded Doppler sonography that was performed routinely in all patients of both groups). The velocity criteria and the plaque's morphology were taken into account for CEA decision-making purposes. As described elsewhere, 13 a peak systolic velocity (PSV) >140 cm/s with spectral broadening throughout systole and an increased end-diastolic velocity were consistent with a stenosis with a $50% reduction in diameter, whereas a PSV >210 cm/s and an end-diastolic velocity between 110 and 140 cm/s were consistent with a $70% stenosis. The 60% stenosis criterion was PSV stenosis / PSV pre-stenosis ¼ 3; for 50% stenosis, this rate was 2; and for 70% stenosis, this rate was 4. All patients of the two groups underwent neurologic assessment by the consultant neurologist on presentation, on awakening from the anesthesia, before discharge from the hospital, and during the follow-up. Statins were administered to all patients with diabetes, dyslipidemia, or extracranial or intracranial artery stenosis; antiplatelet treatment was considered for all patients with diabetes, ischemic heart disease, or extracranial or intracranial or peripheral artery disease. Preoperative preparation of the patient was standardized. The preoperative cardiac workup was tailored to each individual's clinical history, electrocardiographic findings, and symptoms. Patients with evidence of clinically important coronary artery disease underwent echocardiography or dipyridamolethallium stress tests followed by coronary arteriography, as indicated.
All surgical procedures were eversion CEAs performed by the same surgeon in patients under general anesthesia and with routine intraoperative electroencephalographic monitoring for a selective use of intraluminal shunting. Specific perioperative and postoperative phases of the surgical procedure, including technical details of the CEA, have been reported elsewhere. 14, 15 Surveillance protocol. After discharge, visiting nurses monitored the surgical patients' blood pressure and neurologic status. All patients of the two groups were scheduled for regular clinical checkups after 1, 6, and 12 months and then every 6 months during the follow-up. At each visit, patients systematically underwent physical and neurologic assessment by a consultant neurologist and had concomitant duplex ultrasound scans performed by two experienced neurosonographers. All examinations of the two groups were performed with a high-resolution, color- Neurologic events were always classified by the consultant neurologist as follows: transient ischemic attack (TIA), defined as temporary hemispheric symptoms lasting no more than 24 hours, with complete recovery; amaurosis fugax, a transient monocular visual loss; minor stroke, a clinical syndrome of rapidly developing signs or symptoms of focal loss of cerebral function of vascular origin, lasting more than 24 hours but not leading to any handicap or significant impairment in activities of daily living, rated as <3 on the modified Rankin scale 16 ; or major stroke, defined as a focal neurologic deficit lasting more than 30 days and inducing a change in lifestyle, assessed as 3 to 5 on the modified Rankin scale. Brain imaging (CT or magnetic resonance imaging) was performed in all patients presenting a new neurologic deficit after CEA. Cardiac complications were classified by a single cardiologist and included (1) myocardial infarction with a diagnosis based on creatine kinase MB levels and electrocardiographic findings, (2) pulmonary edema confirmed by chest radiography, (3) documented ventricular fibrillation or primary cardiac arrest, and (4) new congestive heart failure requiring a pacemaker. A postoperative electrocardiogram was routinely obtained in all patients with a history of coronary artery disease, congestive heart failure, or arrhythmia (rhythm other than sinus), and cardiac isoenzymes were surveyed in all patients who had new findings at postoperative electrocardiography. Other complications and events observed during the follow-up were recorded in accordance with the guidelines of the Ad Hoc Committee on Reporting Standards for Cerebrovascular Disease, Society for Vascular Surgery/North American Chapter of the International Society of Cardiovascular Surgery. 17 Primary end points were perioperative stroke and death and any ipsilateral ischemic adverse events during the follow-up. Follow-up ranged from 1 to 80 months (median, 4.4 years; mean, 5.6 years).
Statistical analysis. The statistical analysis was performed with the SPSS statistical software (version 12.0.1; SPSS Inc, Chicago, Ill). Patients' demographic data are given as medians, means, and ranges; baseline clinical and diagnostic findings are given in terms of incidence rates.
Frequencies and categorical data were compared with c 2 or Fisher exact test, as appropriate, calculating the odds ratio (OR) with 95% confidence intervals (CIs). The rates of freedom from any ipsilateral ischemic neurologic event and from plaque progression and survival rates were calculated by the Kaplan-Meier method and are reported as "life-table" analyses. Significance was assumed at P < .05. Several data items were analyzed vis-à-vis surgical procedures rather than patients because each perioperative outcome was correlated with the surgical procedure and because patients who underwent bilateral CEAs were exposed to twice the risk of stroke, death, or other complications.
RESULTS
Descriptive analysis. In group 1, 72 CEAs were performed in 69 patients. One patient was scheduled for bilateral CEA at admission, and the carotid with the more severe stenosis was corrected immediately, the other 4 weeks later; in two other cases, a contralateral CEA was performed 19 and 22 months after the first procedure. Table I shows the baseline characteristics of the study population and the comparison between the two groups' variables. Groups 1 and 2 were comparable for all the variables considered, the type of concomitant medication at presentation, and the degree of the ipsilateral carotid stenosis.
Perioperative results. There were no strokes or deaths; one perioperative TIA (1.4%) developed in the territory of the middle cerebral artery contralateral to the side operated on (Table II) . Duplex ultrasound was performed immediately and showed that the revascularized vessel was patent, and cerebral CT and magnetic resonance images were negative for any new ischemic lesion.
Other complications. There was one episode of arrhythmia that was managed conservatively (1.4%). Other surgical complications were two nerve injuries (2.8%; involving a cranial nerve and a cervical nerve) and one neck hematoma (1.4%) requiring surgical evacuation but causing no further complications (Table II) .
Long-term results. Among the 123 patients considered in the study, five (4%) were lost to follow-up, including three patients (three CEAs) in group 1, so a complete follow-up was available for 118 patients. In group 1, there was one late minor stroke (ipsilateral to the side operated on and contralateral to a carotid occlusion that was probably hemodynamic in nature, judging from the CT images). No carotid occlusions or restenoses were detected. In group 2, duplex ultrasound revealed a progression of the ipsilateral carotid lesion in five arteries (9.6%), within a mean 22.4 months (three arteries progressed from 60% to 69% and two arteries from 70% to 90%). Four of the patients involved (7.7%) developed ipsilateral neurologic symptoms (one TIA and three minor strokes), with ultrasonographic features of intraplaque hemorrhage confirmed by CT images. A sixth patient experienced an ipsilateral minor stroke 19 months after enrollment in the study, and duplex ultrasound showed intraplaque hemorrhage but no plaque progression. The five patients who had become symptomatic (9.6%) were all taking antiplatelet and statin medication at presentation and when their neurologic event occurred. The consultant neurologist confirmed their diagnosis, and they underwent CEA within 2 weeks of the onset of their ischemic event. The patient with asymptomatic plaque progression (from 70% to 85%) continued on BMT (1.9%) and was monitored periodically with ultrasound.
The 5-year rate of freedom from cerebral ischemic events showed a significant benefit for group 1 compared with group 2 (98% vs 84%; OR, 0.15; 95% CI, 0.04-0.88; P ¼ .04; Fig 1) , and so did the 5-year rate of freedom from overall plaque progression (100% vs 79%; OR, 0; 95% CI, 0.01-0.60; P ¼ .01; Fig 2) , with no differences emerging when plaque progression developed with symptoms (100% vs 88%; log-rank test, P ¼ .06) or no symptoms (100% vs 91%; log-rank test, P ¼ .12). Table III shows the compliance with BMT and lifestyle changes in the two groups. There were 10 late deaths (15.1%) among patients who underwent CEA and six (11.5%) among those who did not. The cause was primarily cardiac related (n ¼ 9; 56.2%; Table IV). At 3 and 5 years, the survival rates were 75% 6 8.8% and 65.6% 6 9.6% in group 1 and 76.7% 6 8.4% and 68.2% 6 9.8% in group 2 (OR, 1.25; 95% CI, 0.46-3.39; P ¼ .65; Fig 3) .
DISCUSSION
Two major RCTs investigated the role of CEA in patients with ASCS, reporting a combined risk of perioperative stroke and death of 1.5% in the ACAS 2 and 3% in the ACST, 3 with a significantly lower 5-year stroke risk for patients who underwent CEA than for those who did not (5.1% vs 11% in the ACAS 2 and 6.4% vs 11.8% in the ACST 3 ). The benefit was particularly relevant for patients younger than 75 years. 2, 3 In both studies, the absolute reduction in the stroke risk associated with CEA was approximately 1% a year, meaning that the benefit was likely to be substantial only in patients with a longer life expectancy. On the basis of these findings, a certain skepticism has surrounded the pertinence of CEA for ASCS in people in their 80s, significantly curtailing its indication in such patients. Current generally accepted guidelines recommend that CEA should be considered only for elderly people with a life expectancy of at least 3 to 5 years and evidence suggesting a perioperative stroke and mortality risk <3% 18 ; otherwise, BMT should be advised. On the other hand, although age is a significant predictor of life expectancy, the conviction that mortality and functional decline continue to increase proportionally with increasing age 19 has recently been questioned. The expected yearly mortality appears to be the same at 90 years old as at 85 years old and even seems to fall by the age of 100 years. 20 Noninvasive medical care has achieved a reduction in the stroke risk for many people, but its efficacy has not been verified among high-risk patients with ASCS who would otherwise be candidates for CEA.
21-24
The results of this observational study suggest that (1) CEA is a safe, effective, and durable procedure for patients in their 80s with ASCS; (2) for such elderly patients, CEA is more effective than BMT alone in preventing the risk of ipsilateral ischemic events, even if this does not extend patients' life expectancy. Leaving aside the RCTs on asymptomatic carotid disease, it would be difficult to draw a useful comparison with other studies because of the paucity of investigations focusing explicitly on the management of octogenarians with ASCS, but our perioperative findings compare favorably with those reported in earlier experiences. 25, 26 In a series of 2217 CEAs performed during a 12-year period in 1961 patients, there were 334 symptomatic and asymptomatic patients (360 CEAs) aged 80 years or more; there was no difference in the combined perioperative stroke/death rate between the octogenarians with ASCS and younger patients (0.9% vs 1.4%; P ¼ .86), although the stroke/death rate was higher in the octogenarian cohort as a whole (3.1% vs 1.5%; P ¼ .04). 25 On the basis of data from the Carotid Artery Revascularization and Endarterectomy (CARE) registry, among 2773 patients aged >70 years with ASCS, the combined outcomes for stroke, death, and myocardial infarction did not differ statistically between those >75 years old and those <75 years old (3.1% vs 2.0%; P ¼ .08), although mortality was significantly higher among the >75-yearolds (0.7% vs 0%; P ¼ .006). 26 At 3 and 5 years, our elderly patients' mortality rates were comparable with the figures reported by others concerning pooled data on symptomatic and asymptomatic subjects. 25, 27, 28 Although the causes of two late deaths in our series were not ascertained (so one or both might have been stroke related), there were no late strokerelated deaths in our elderly CEA population, so CEA does not seem to offer a prolonged survival advantage. The fact that the only late ipsilateral ischemic stroke occurred in a watershed zone would support the efficacy of CEA in preventing late strokes due to carotid disease but would imply that CEA cannot prevent all late strokes. With recent improvements in medical management, including patient lifestyle changes (avoiding smoking, monitoring blood pressure and cholesterol) and triple medical therapy (with lipid-lowering, antihypertensive, and antiplatelet drugs), the risk of stroke in patients with ASCS is reportedly much lower than it was when the ACAS and ACST were conducted. 29, 30 This evidence has supported the opinion that modern BMT alone suffices for ASCS, reducing the stroke risk to levels that make CEA unjustified. This conviction comes mainly from two amply cited meta-analyses 7, 31 and several prospective populationbased studies, 21,23,32-34 none of which tested the efficacy of CEA plus BMT vs BMT alone in terms of reducing the risk of stroke, however.
24
The 5-year rate of freedom from stroke of 98% in our octogenarians who underwent CEA plus BMT indicates that most of them lived the rest of their lives without experiencing any strokes, whereas the risk of late ipsilateral ischemic cerebral events was statistically higher in their medically managed counterparts, even though more than 80% of them were taking statins and 98% were receiving antiplatelet/antithrombotic medication. This finding is supported by the 5.7% incidence of cerebrovascular ischemic events at 1 year in a large cohort of patients with ASCS (mean age, 71.3 6 9.5 years), 70% of them receiving statins and 87% receiving antihypertensive drugs at baseline. 10 In another large study on 900 carotid arteries with moderate (50%-69%) asymptomatic carotid lesions, 11% of patients developed an ipsilateral ischemic event with a 58% incidence of stroke during a mean follow-up of 3.6 years, despite 86.5% of them taking antiplatelet agents and 87% of them taking lipid-lowering drugs. 35 Among the patients who became symptomatic, 40% showed a progression of the plaque (from moderate to severe), but no data are available on the plaque's morphology. 35 In our series, plaque progression was identified in four of the five patients in group 2 who developed symptoms despite BMT and thus underwent CEA. They showed clear changes in their plaque morphology due to local complications such as ulceration and intraplaque hemorrhage. This picture correlates well with other reports, 35 confirming our previous observation that certain features typical of plaque instability may be uninfluenced by statin and antiplatelet therapy and often are responsible for medically refractory ipsilateral ischemic cerebral events. 36, 37 This raises some doubts about the role of statins in preventing stroke and the influence of antiplatelet agents on carotid disease progression, although compliance with cardiovascular prevention differs between clinical trials and daily clinical practice, and this needs to be taken into account.
The 3-and 5-year cumulative survival in elderly CEA patients with ASCS was comparable with that of their medically treated counterparts, demonstrating that neither CEA plus BMT nor BMT alone seems to significantly affect such patients' life expectancy.
Limitation of the study. Our finding should be interpreted bearing the study's limitations in mind. First, although the data were collected prospectively, the analysis was retrospective in nature. Second, the study was deliberately limited to recent years of our clinical experience to involve a larger number of patients managed with BMT on the basis of current recommendations. 18, 38 This may have led to a selection bias because healthier patients may be referred for CEA nowadays, although we cannot say for sure. In addition, the size of the sample is small, the number of perioperative events nil, and the incidence of late adverse cerebrovascular ischemic events low, so the resulting lack of power makes any definitive statistical analysis impossible. However, the follow-up was long enough to underline the importance of our data and to support our conclusions. Third, as with any chronic treatment, tolerance/compliance decreases over time, so it may be that not all patients continued to take the recommended medication regularly. The patients' adherence to prescribed smoking bans, close monitoring of hypertension and diabetes, and other lifestyle changes are also just as important as their use of lipid-lowering and antiplatelet drugs, but this aspect is not easily documented within the confines of a retrospective study design.
CONCLUSIONS
This study has suggested that CEA is a safe, effective, and durable procedure for patients in their 80s with ASCS. Despite the marked improvement in BMT in recent years for the prevention of stroke in patients with ASCS, to assume that it may suffice alone to prevent ipsilateral adverse ischemic accidents is hazardous and not supported by randomized data. On the basis of the results of our observational analysis, CEA plus BMT seems still preferable to the best medical care alone for preventing stroke in octogenarians with ASCS. Randomized trials on larger samples and an extended follow-up are needed to compare CEA with BMT in asymptomatic patients at higher risk of stroke.
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